The Rajasthan Drug Control Commissionerate has escalated action after quality-testing revealed that five of the 18 medicine samples collected from an unlicensed warehouse in Bhiwadi were found substandard, Principal Secretary (Medical and Health) Gayatri Rathore confirmed on Thursday, 10 September. The findings have triggered inspections at the manufacturing units responsible for the flagged batches.

The Raid and What Was Seized

Authorities conducted the operation at the unlicensed Bhiwadi facility on the basis of confidential intelligence. The crackdown yielded approximately 1,500 cartons of medicines and other materials valued at roughly ₹4 crore. In compliance with court orders, the seized stock has been placed under the custody of the Drug Control Officer.

Medicines manufactured and marketed by several companies were found on the premises during the raid. A total of 18 samples were collected for quality assessment — of which five have now been declared substandard by laboratory testing.

What the Commissionerate Has Ordered

Drug Control Commissioner Avichal Chaturvedi said inspection teams have been dispatched to each of the concerned manufacturing units. These teams will carry out a detailed scrutiny of manufacturing records, raw materials, quality-control logs, batch production records, and documents related to the distribution and supply chain of the implicated batches.

The inspections will also verify whether the manufacturing, quality testing, storage, and distribution of the medicines were carried out in line with prescribed standards and regulatory norms under the Drugs and Cosmetics Act.

Regulatory Stance on Unlicensed Pharma Trade

Commissioner Chaturvedi underlined the Commissionerate's zero-tolerance approach, stating that no negligence would be tolerated in matters of medicine quality and public health, or in cases involving unlicensed pharmaceutical operations. Legal action will be pursued against all individuals, institutions, and parties implicated once the investigation establishes the facts.

Notably, the operation highlights a pattern of substandard and spurious medicines surfacing in warehouses operating outside the regulatory framework — a concern that drug regulators across multiple Indian states have flagged in recent years.

What Happens Next

The Rajasthan Drug Control Commissionerate has indicated that action under the Drugs and Cosmetics Act will follow upon completion of the manufacturing-unit inspections. The outcome of those inspections is expected to determine criminal and civil liability for the parties involved. Citizens who may have purchased medicines from unlicensed sources in the Bhiwadi area are advised to consult healthcare providers if in doubt about the authenticity of their medication.